Enzyme, Transferase, Choline/carnitine acyltransferase family
01
Overview
Carnitine O-acetyltransferase (CRAT) is a mitochondrial enzyme that catalyzes the reversible exchange of acetyl groups between coenzyme A (CoA) and carnitine. This reaction produces either acetylcarnitine plus CoA from carnitine plus acetyl-CoA or vice versa. The enzyme plays an essential role in cellular energy homeostasis by regulating the pool sizes of free CoA and acyl-CoAs within mitochondria. Structurally, CRAT consists of two domains with similar backbone folds; its active site features a catalytic histidine residue critical for substrate deprotonation during catalysis. Deficiency in this enzyme leads to severe neurological and cardiac symptoms due to impaired energy metabolism. It has emerged as an attractive therapeutic target for metabolic diseases like type 2 diabetes and obesity because modulation affects lipid utilization pathways without directly altering glucose handling mechanisms.[1][3][4][5][6]
Other names
Carnitine acetyltransferaseCrATCAT (less common, can be ambiguous)EC 2.3.1.7 (Enzyme Commission number)
02
Mechanism of action
Drugs or small molecules targeting CRAT would typically act by inhibiting or modulating its enzymatic activity—altering the transfer of acetyl groups between CoA and carnitine, thereby affecting mitochondrial metabolism and fatty acid oxidation rates[3].
03
Biological functions
Catalyzes the reversible transfer of acetyl groups between acetyl-CoA and carnitineMaintains the balance of acetyl-CoA and CoA in mitochondriaFacilitates transport of acetyl groups across intracellular membranesInvolved in excretion of excess or harmful acyl molecules as acylcarnitinesRequired for cell cycle progression from G1 to S phase
04
Disease associations
Neurological disorders (deficiency can cause neurological problems)Cardiovascular disease (deficiency can cause heart problems)Metabolic diseases such as type 2 diabetes and obesity (therapeutic target)
05
Safety considerations
Potential safety concerns include disruption of mitochondrial energy metabolism if enzyme function is excessively inhibitedthis could lead to impaired fatty acid oxidation, accumulation of toxic metabolites, neurological symptoms, cardiac dysfunction, or other metabolic disturbances in susceptible individuals.
06
Interacting drugs
No specific approved drugs are listed that directly target CRAT, but it is considered a potential drug target for metabolic diseases such as diabetes and obesity due to its role in fatty acid metabolism[3][5]. Some experimental inhibitors have been studied.
07
Biomarkers
Reduced activity or expression levels of CRAT may serve as biomarkers for certain neurological conditions, heart disease, or Alzheimer's diseaseinherited deficiency is also a diagnostic marker for rare metabolic disorders
Beyond the preview
Go deeper on Carnitine O-acetyltransferase (CRAT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carnitine O-acetyltransferase (CRAT).